FindTrial
Sign In

OVACURE-2: Adoptive T cell therapy plus low dose IL-2 (IL-2ld) as first line neoadjuvant therapy in patients with stage III/IV ovarian cancer

Status
Not yet recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-522659-24-00
Enrollment
30
Registered
2025-12-03
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian carcinoma

Brief summary

mmunotherapy related grade III/IV NCI-CTC toxicity

Detailed description

All grade NCI CTC toxicity, CD8/CD4/MDSC, M1/2, Treg

Interventions

DRUGALDESLEUKIN
DRUGTIL cells

Sponsors

Leids Universitair Medisch Centrum (LUMC)
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
mmunotherapy related grade III/IV NCI-CTC toxicity—

Secondary

MeasureTime frame
All grade NCI CTC toxicity, CD8/CD4/MDSC, M1/2, Treg—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026